Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...
Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (ACRV) with an Overweight rating without a price target The company has two ...
Cantor Fitzgerald analyst C J Muse maintained a Hold rating on Intel (INTC – Research Report) yesterday and set a price target of $22.00. The ...
Hosted on MSN16h
Cantor Fitzgerald Upgrades Lam Research (LRCX)Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (NasdaqGS:LRCX) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback